Mixtures of SCFA, composed according to physiologically available concentrations in the gut lumen, modulate histone acetylation in human HT29 colon cancer cells.
Intake of fibre has beneficial properties on gut health. Butyrate, a product of bacterial gut fermentation, is thought to contribute to positive effects by retarding growth and enhancing apoptosis of tumour cells. One mechanism is seen in its capacity to modulate histone acetylation and thereby transcriptional activity of genes. Next to butyrate, propionate and acetate are also major products of gut fermentation and together they may exert different potencies of cellular effects than butyrate alone. Since virtually nothing is known on combination effects by SCFA mixtures, here we had the aim to assess how physiological relevant concentrations and mixtures of SCFA modulate histone acetylation in human colon cells. HT29 colon cancer cells were incubated with mixtures of butyrate, acetate and propionate and with the individual compounds as controls. Histone acetylation was determined with acid-urea gel electrophoresis and immunoblotting. Acetylated histones slowly increased over 24 h and persisted up to 72 h in butyrate-treated HT29 cells. Butyrate (5-40 mM) and propionate (20-40 mM) enhanced histone acetylation significantly after 24 h incubation, whereas acetate (2.5-80 mM) was ineffective. Mixtures of these SCFA also modulated histone acetylation, mainly due to additive effects of butyrate and propionate, but not due to acetate. In conclusion, physiological concentrations of propionate together with butyrate could have more profound biological activities than generally assumed. Together, these SCFA could possibly mediate important processes related to an altered transcriptional gene activation and thus contribute to biological effects possibly related to cancer progression or prevention.
Kiefer
Jeannette
J
Department of Nutritional Toxicology, Institute for Nutrition, Friedrich-Schiller-University, Dornburger Str. 25, D-07743 Jena, Germany.
Beyer-Sehlmeyer
Gabriele
G
Pool-Zobel
Beatrice L
BL
D000085:Acetates / Q000008:administration & dosage / Q000493:pharmacokinetics; D000107:Acetylation / Q000187:drug effects; D002087:Butyrates / Q000008:administration & dosage / Q000493:pharmacokinetics; D003470:Culture Media; D004305:Dose-Response Relationship, Drug; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005232:Fatty Acids, Volatile / Q000008:administration & dosage / Q000493:pharmacokinetics*; D019073:HT29 Cells; D006657:Histones / Q000378:metabolism*; D006801:Humans; D006877:Hydroxamic Acids / Q000494:pharmacology; D007413:Intestinal Mucosa / Q000378:metabolism; D011422:Propionates / Q000008:administration & dosage / Q000493:pharmacokinetics
D000085:Acetates; D002087:Butyrates; D003470:Culture Media; D004791:Enzyme Inhibitors; D005232:Fatty Acids, Volatile; D006657:Histones; D006877:Hydroxamic Acids; D011422:Propionates; C012589:trichostatin A